Slow-and-Steady Is the Right Approach for Evaluating Cell Therapy for Autoimmune Diseases
February 18th 2024Peter A. Merkel, MD, MPH, the chief of the Division of Rheumatology and a professor of medicine and professor of epidemiology at Penn Medicine, discussed clinical trial design considerations for this emerging field.
FDA Greenlights Lifileucel for Unresectable, Metastatic Melanoma Via Accelerated Approval
February 16th 2024Iovance’s tumor infiltrating lymphocyte (TIL) therapy is the first cellular therapy to earn this indication, with the phase 3, confirmatory TILVANCE-301 trial set to verify its clinical benefit.
Bruce Cree, MD, PhD, MAS, on Misconceptions About CAR-T in Autoimmune Disease
February 15th 2024The clinical research director of the UCSF Multiple Sclerosis Center discussed the importance of rigorous clinical trial design for determining whether CAR-T will truly be of benefit in autoimmune disease.
Peter A. Merkel, MD, MPH, on Approaching Clinical Trial Design for CAR-T in Autoimmune Disease
February 10th 2024The chief of the Division of Rheumatology and professor of medicine and professor of epidemiology at Penn Medicine discussed the panel he participated in at the inaugural Cell Therapy for Autoimmune Disease Summit.